Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis

BMJ Open

Volumn 4, Issue 8, 2014, Pages

  Nakashita, Tamao ^a   Ando, Katsutoshi ^b   Kaneko, Norihiro ^a   Takahashi, Kazuhisa ^b   Motojima, Shinji ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; MUC1 PROTEIN, HUMAN; MUCIN 1; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RADIOGRAPHY; RETROSPECTIVE STUDY;

ABATACEPT; ADALIMUMAB; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ETANERCEPT; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INFLIXIMAB; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MUCIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905910303     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005615     Document Type: Article

References (29)

1. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143:814-24.
2. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003;115:371-6. (Pubitemid 37311254)
3. Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832-6. (Pubitemid 350067642)
4. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52:53-61.
5. Libby D, White DA. Pulmonary toxicity of drugs used to treat systemic autoimmune diseases. Clin Chest Med 1998;19:809-21. (Pubitemid 29013320)
6. Barrera P, Laan RF, van Riel PL, et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994;53:434-9. (Pubitemid 24252489)
7. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
8. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985;131:770-7. (Pubitemid 15066866)
9. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002;122:1093-6.
10. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biologic agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72(Suppl 2):ii2-34.
11. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR 2004;53:683-6.
12. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:189-94. (Pubitemid 351183307)
13. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2011;21:343-51.
14. Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:622-8. (Pubitemid 43334590)
15. Tengstrand B, Emestam S, Engvall IL, et al. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen 2005;102:3788-90.
16. Kramer N, Chuzhin Y, Kaufman LD, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:670-1. (Pubitemid 35461322)
17. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, et al . Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41:256-64.
18. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007;34:1151-4. (Pubitemid 46774864)
19. Kawashiri SY, Kawakami A, Sakamoto N, et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012;32:4023-6.
20. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008;168:159-66. (Pubitemid 351185882)
21. Oikonomou N, Harokopos V, Zalevsky J, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS ONE 2006;1:e108.
22. Hasegawa M, Fujimoto M, Kikuchi K, et al. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997;24:663-5. (Pubitemid 27146081)
23. Piguet PF, Ribaux C, Karpuz V, et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993;143:651-5. (Pubitemid 24058221)
24. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55.
25. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-27.
26. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43:613-26.
27. Distler JH, Hagen C, Hirth A, et al. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappa B and simian virus 40 promoter factor 1 pathways. Mol Pharmacol 2004;65:389-99. (Pubitemid 38134267)
28. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002;3:13.
29. Japan College of Rheumatology. Guideline of TNF-alpha inhibitors for rheumatoid arthritis. 2012. http://www.ryumachi-jp.com/info/TNF-chart.html [Japanese].